Objective: To evaluate the efficacy of imidafenacin on nocturia and sleep disorder in patients with overactive bladder (OAB). Patients and Methods: A prospective multicenter study of imidafenacin 0.1 mg twice daily for patients with OAB and nocturia was conducted. At baseline and at week 4 and 8, patients were assessed using the overactive bladder symptom score (OABSS), frequency volume charts (FVC) and the Pittsburgh Sleep Quality Index (PSQI). Results: Treatment with imidafenacin significantly improved OAB symptoms. Imidafenacin also improved PSQI, especially subjective sleep quality, sleep latency and daytime dysfunction. In FVC, the number of daytime voids and nighttime voids significantly decreased and average voided volume significantly increased after imidafenacin. Subanalysis of FVC based on the patients’ age revealed that nocturnal polyuria was more often found in patients aged 75 years or over than in those aged under 75 years (79 vs. 55%, p < 0.05). Treatment with imidafenacin significantly reduced the nocturnal polyuria index only in patients aged 75 years or over. Conclusions: Imidafenacin can improve nocturia and sleep disorder in patients with OAB. The efficacy of imidafenacin on nocturia is attributable to an increase in bladder capacity and a decrease in nocturnal urine volume. We conclude that imidafenacin is an effective and safe drug for nocturia in patients with OAB.

1.
Homma Y, Yamaguchi O, Hayashi K, Neurogenic Bladder Society Committee: Epidemiologic survey of lower urinary tract symptoms in Japan. Urology 2006;68:560–564.
2.
Yoshimura K, Terada N, Matsui Y, Terai A, Kinukawa N, Arai Y: Prevalence of and risk factors for nocturia: analysis of a health screening program. Int J Urol 2004;11:282–287.
3.
Nakagawa H, Niu K, Hozawa A, Ikeda Y, Kaiho Y, Ohmori-Matsuda K, et al: Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J Urol 2010;184:1413–1418.
4.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al: The standardization of the terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–178.
5.
Homma Y, Paick JS, Lee JG, Kawabe K, Japanese and Korean Tolterodine Study Group: Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 2003;92:741–747.
6.
Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al: Randomized, double-blind, placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with overactive bladder. BJU Int 2004;93:303–310.
7.
Kaplan SA, Roehrborn CG, Dmochoi R, Rovner ES, Wang JT, Guan Z: Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006;68:328–332.
8.
Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z: Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006;67:731–736.
9.
Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, et al: Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int 2007;100:579–587.
10.
Kobayashi F, Yageta Y, Yamazaki T, Wakabayashi E, Inoue M, Segawa M, et al: Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Arzneimittelforschung 2007;57:147–154.
11.
Homma Y, Yamaguchi O, Imidafenacin Study Group: A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2009;16:499–506.
12.
Yamaguchi O, Nishizawa O, Takeda M, Yokoyama O, Homma Y, Kakizaki H, et al: Clinical guidelines for overactive bladder. Int J Urol 2009;16:126–142.
13.
Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213.
14.
Doi Y, Minowa M, Uchiyama M, Okawa M, Kim K, Shibui K, et al: Psychometric assessment of subjective sleep quality using the Japanese version of the Pittsburgh Sleep Quality Index (PSQI-J) in psychiatric disordered and control subjects. Psychiatry Res 2000;97:165–172.
15.
Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, et al: A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464–470.
16.
Weiss JP, Blaivas JG, Jones M, Wang JT, Guan Z, 037 Study Group: Age related pathogenesis of nocturia in patients with overactive bladder. J Urol 2007;178:548–551.
17.
Sugaya K, Nishijima S, Oda M, Owan T, Miyazato M, Ogawa Y: Biochemical and body composition analysis of nocturia in the elderly. Neurourol Urodyn 2008;27:205–211.
18.
Watanabe N, Akino H, Tanaka I, Nagase K, Yokoyama O: Antidiuretic effect of anticholinergic agents depend on c-fiber afferent nerves in the bladder. 40th Annu Meet Int Continence Soc, Toronto, 2010, abstract 493.
19.
Brubaker L, FitzGerald MP: Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J 2007;18:737–741.
20.
Yokoyama O, Yamaguchi O, Kakizaki H, Itoh N, Yokota T, Okada H, et al: Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. J Urol 2011;186:170–174.
21.
Bliwise DL, Foley DJ, Vitiello MV, Ansari FP, Ancoli-Israel S, Walsh JK: Nocturia and disturbed sleep in the elderly. Sleep Med 2009;10:540–548.
22.
Coyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E: The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 2003;92:948–954.
23.
Diefenbach K, Arold G, Wollny A, Schwantes U, Haselmann J, Roots I: Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged >50 years. BJU Int 2005;95:346–349.
24.
Wada N, Watanabe M, Kita M, Osanai H, Yamaguchi S, Numata A, et al: Efficacy and safety of propiverine and solifenacin for the treatment of female patients with overactive bladder: a crossover study. LUTS 2011;3:36–42.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.